[ Price : $8.95]
FDA approves an Entasis Therapeutics NDA for Xacduro (sulbactam and durlobactam for injection), a new treatment for hospital-acqui...[ Price : $8.95]
FDA agrees to a PolyPid Phase 3 trial (SHIELD II) design revision evaluating D-PLEX 100 (doxycycline) for preventing abdominal col...[ Price : $8.95]
FDA denies a Public Citizen petition that sought a Boxed Warning for all sodium-glucose cotransporter-2 inhibitor drugs contraindi...[ Price : $8.95]
FDA updates its CDRH Portal to allow users to track the progress of pre-submissions for obtaining feedback on potential marketing ...[ Price : $8.95]
FDA approves a Blueprint Medicines NDA for Ayvakit (avapritinib) for treating adults with indolent systemic mastocytosis.[ Price : $8.95]
Novo Nordisk plans to file an NDA for obesity drug semaglutide 50 mg tablets after announcing that the Phase 3a OASIS 1 trial met ...[ Price : $8.95]
Rain Oncology says it will cease further development of milademetan in dedifferentiated liposarcoma after reporting disappointing ...[ Price : $8.95]
Federal Register notice: FDA withdraws approval of Abbotts NDA for Cyclert (pemoline) tablets, indicated for treating attention-de...